Benjamin Schoenbeck
He joined Sysmex Europe as a Product Manager for Haematology, supporting the EMEA region, and later focused on the Middle East market based in Dubai, addressing laboratory workflows and clinical needs. Since 2020, Dr. Schoenbeck has served as Scientific Marketing Manager for Urinalysis in the EMEA region, supporting clinical studies and expanding the application of Sysmex urinalysis solutions through clinical relationships. As Senior Manager Scientific Marketing he is now extending these activities over the fields of urinalysis, point-of-care solutions and immunochemistry within the complex clinical decision-making network. In 2023, he completed an MBA in Marketing Management to further strengthen customer-centric and clinically driven strategies.
Aiheet
The power of M2BPGi in the non-invasive assessment of fibrosis in Chronic Liver Disease
Chronic liver disease (CLD) represents a major global health burden, with progressive fibrosis being a key determinant of clinical outcomes. Accurate, non-invasive assessment of liver fibrosis is essential for risk stratification, disease monitoring, and therapeutic decision-making. Mac-2 binding protein glycosylation isomer (M2BPGi) has emerged as a promising serum biomarker reflecting fibrotic remodelling and disease progression across multiple CLD aetiologies.
This presentation will discuss the biological rationale and clinical utility of M2BPGi, focusing on its analytical determination using the Sysmex HISCL® (High-sensitive Chemiluminescence Enzyme Immunoassay) platform, which enables fully automated, standardised, and reproducible quantification in high-throughput clinical laboratories. Clinical evidence supporting the performance of M2BPGi in fibrosis staging, prediction of disease progression, and prognostic assessment will be reviewed. Integration of M2BPGi testing on the Sysmex HISCL platform may improve clinical workflows and patient management by enabling early detection and longitudinal monitoring of liver fibrosis.